Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance–related polycystic ovary syndrome

摘要: Abstract Objective: To investigate the effect of troglitazone, a new antidiabetic agent that improves insulin resistance, on endocrine, metabolic, and ovulatory performance in women with resistance–related polycystic ovary syndrome (PCOS). Design: Prospective clinical study. Setting: Infertility outpatient clinic, Niigata University Hospital, Niigata, Japan. Patient(s): Thirteen PCOS resistance. Intervention(s): Troglitazone (400 mg/d) was administered for 12 weeks. Main Outcome Measure(s): Insulin other hormone (gonadotropins, androgens) levels; various parameters relating to glucose lipid metabolism before, during, after troglitazone administration; ovulation rate. Result(s): The mean (±SD) fasting concentration significantly reduced, from 18.3 ± 8.9 10.5 7.1 μU/mL. LH level reduced 9.7 3.4 4.8 3.9 mIU/mL testosterone 0.9 0.5 0.3 ng/mL accordance. Atherosclerotic levels also were normalized. Before administration, rate during clomiphene citrate therapy 34.9% per cycle (15/43). This increased 72.7% (8/11) coadministration. Further, an 42.3% (11/26) achieved alone. Conclusion(s): In reduction hyperinsulinemia is produced by hyperandrogenism characterizes PCOS, restoring ovulation.